Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Stock Competitors & Peer Comparison
See AMLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMLX | $26.34 | -4.74% | 3.3B | -17.56 | -$1.50 | N/A |
| VRTX | $499.74 | -1.77% | 126.7B | 26.26 | $19.03 | N/A |
| MRNA | $218.01 | -7.82% | 87B | -26.75 | -$8.15 | N/A |
| REGN | $790.74 | -0.70% | 81.4B | 17.33 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $819.14 | -3.21% | 51.5B | 29.53 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $369.06 | -1.34% | 39.4B | 64.98 | $5.68 | N/A |
| RVMD | $177.96 | -5.97% | 38.1B | -20.18 | -$8.82 | N/A |
| RVMDW | $8.40 | -13.98% | 34.8B | -0.95 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
AMLX vs VRTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, VRTX has a market cap of 126.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while VRTX trades at $499.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas VRTX's P/E ratio is 26.26. In terms of profitability, AMLX's ROE is -0.53%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, AMLX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
AMLX vs MRNA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MRNA has a market cap of 87B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MRNA trades at $218.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MRNA's P/E ratio is -26.75. In terms of profitability, AMLX's ROE is -0.53%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, AMLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
AMLX vs REGN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, REGN has a market cap of 81.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while REGN trades at $790.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas REGN's P/E ratio is 17.33. In terms of profitability, AMLX's ROE is -0.53%, compared to REGN's ROE of +0.14%. Regarding short-term risk, AMLX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
AMLX vs VRNA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas VRNA's P/E ratio is -102.80. In terms of profitability, AMLX's ROE is -0.53%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, AMLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
AMLX vs ARGX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ARGX has a market cap of 51.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ARGX trades at $819.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ARGX's P/E ratio is 29.53. In terms of profitability, AMLX's ROE is -0.53%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, AMLX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
AMLX vs SGEN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas SGEN's P/E ratio is -57.19. In terms of profitability, AMLX's ROE is -0.53%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, AMLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
AMLX vs ONC Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ONC trades at $369.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ONC's P/E ratio is 64.98. In terms of profitability, AMLX's ROE is -0.53%, compared to ONC's ROE of +0.14%. Regarding short-term risk, AMLX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ONC's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
AMLX vs RVMD Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RVMD has a market cap of 38.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RVMD trades at $177.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RVMD's P/E ratio is -20.18. In terms of profitability, AMLX's ROE is -0.53%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, AMLX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
AMLX vs RVMDW Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RVMDW has a market cap of 34.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RVMDW trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RVMDW's P/E ratio is -0.95. In terms of profitability, AMLX's ROE is -0.53%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, AMLX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
AMLX vs ALNY Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ALNY has a market cap of 31B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ALNY trades at $231.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ALNY's P/E ratio is 41.79. In terms of profitability, AMLX's ROE is -0.53%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, AMLX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
AMLX vs ROIV Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ROIV has a market cap of 24.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ROIV trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ROIV's P/E ratio is -31.90. In terms of profitability, AMLX's ROE is -0.53%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, AMLX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
AMLX vs INCY Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while INCY trades at $113.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas INCY's P/E ratio is 15.20. In terms of profitability, AMLX's ROE is -0.53%, compared to INCY's ROE of +0.30%. Regarding short-term risk, AMLX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
AMLX vs UTHR Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, UTHR has a market cap of 22.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while UTHR trades at $533.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas UTHR's P/E ratio is 19.07. In terms of profitability, AMLX's ROE is -0.53%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, AMLX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
AMLX vs GMAB Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, GMAB has a market cap of 22.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while GMAB trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas GMAB's P/E ratio is 27.87. In terms of profitability, AMLX's ROE is -0.53%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, AMLX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check GMAB's competition here
BioNTech SE (NASDAQ: BNTX)
AMLX vs BNTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BNTX trades at $87.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BNTX's P/E ratio is -11.37. In terms of profitability, AMLX's ROE is -0.53%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, AMLX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
AMLX vs INSM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, INSM has a market cap of 21B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while INSM trades at $96.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas INSM's P/E ratio is -23.42. In terms of profitability, AMLX's ROE is -0.53%, compared to INSM's ROE of -1.11%. Regarding short-term risk, AMLX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
AMLX vs BGNE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BGNE's P/E ratio is -22.55. In terms of profitability, AMLX's ROE is -0.53%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, AMLX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
AMLX vs DNA-WT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, AMLX's ROE is -0.53%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, AMLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
AMLX vs EXEL Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, EXEL has a market cap of 15.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while EXEL trades at $62.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas EXEL's P/E ratio is 17.78. In terms of profitability, AMLX's ROE is -0.53%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, AMLX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
AMLX vs ASND Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ASND trades at $225.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ASND's P/E ratio is -93.07. In terms of profitability, AMLX's ROE is -0.53%, compared to ASND's ROE of +1.90%. Regarding short-term risk, AMLX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
AMLX vs HALO Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, HALO has a market cap of 13.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while HALO trades at $121.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas HALO's P/E ratio is 22.73. In terms of profitability, AMLX's ROE is -0.53%, compared to HALO's ROE of +1.81%. Regarding short-term risk, AMLX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
AMLX vs NBIX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, NBIX has a market cap of 13.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while NBIX trades at $135.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas NBIX's P/E ratio is 19.61. In terms of profitability, AMLX's ROE is -0.53%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, AMLX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
AMLX vs JAZZ Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, JAZZ has a market cap of 13.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while JAZZ trades at $210.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas JAZZ's P/E ratio is 7.84. In terms of profitability, AMLX's ROE is -0.53%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, AMLX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
AMLX vs BBIO Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BBIO trades at $66.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BBIO's P/E ratio is -17.75. In terms of profitability, AMLX's ROE is -0.53%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, AMLX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
AMLX vs KRTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas KRTX's P/E ratio is -28.09. In terms of profitability, AMLX's ROE is -0.53%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, AMLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check KRTX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
AMLX vs SMMT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while SMMT trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas SMMT's P/E ratio is -13.06. In terms of profitability, AMLX's ROE is -0.53%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, AMLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check SMMT's competition here
Bio-Techne Corporation (NASDAQ: TECH)
AMLX vs TECH Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TECH trades at $72.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TECH's P/E ratio is 37.41. In terms of profitability, AMLX's ROE is -0.53%, compared to TECH's ROE of +0.09%. Regarding short-term risk, AMLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
AMLX vs RNAM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RNAM's P/E ratio is -17.39. In terms of profitability, AMLX's ROE is -0.53%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, AMLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
AMLX vs BMRN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BMRN trades at $54.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BMRN's P/E ratio is 26.30. In terms of profitability, AMLX's ROE is -0.53%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, AMLX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
AMLX vs MDGL Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MDGL has a market cap of 10.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MDGL trades at $449.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MDGL's P/E ratio is -35.12. In terms of profitability, AMLX's ROE is -0.53%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, AMLX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check MDGL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
AMLX vs PCVX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while PCVX trades at $63.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas PCVX's P/E ratio is -8.34. In terms of profitability, AMLX's ROE is -0.53%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, AMLX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
AMLX vs IBRX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, IBRX has a market cap of 9.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while IBRX trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas IBRX's P/E ratio is -9.46. In terms of profitability, AMLX's ROE is -0.53%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, AMLX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
AMLX vs RXDX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RXDX's P/E ratio is -56.47. In terms of profitability, AMLX's ROE is -0.53%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, AMLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
AMLX vs KRYS Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while KRYS trades at $316.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas KRYS's P/E ratio is 39.67. In terms of profitability, AMLX's ROE is -0.53%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, AMLX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
AMLX vs NUVL Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas NUVL's P/E ratio is -21.79. In terms of profitability, AMLX's ROE is -0.53%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, AMLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
AMLX vs TXG Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TXG trades at $69.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TXG's P/E ratio is -118.41. In terms of profitability, AMLX's ROE is -0.53%, compared to TXG's ROE of -0.09%. Regarding short-term risk, AMLX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
AMLX vs CRNX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CRNX's P/E ratio is -16.86. In terms of profitability, AMLX's ROE is -0.53%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, AMLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CRNX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
AMLX vs TWST Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TWST has a market cap of 8.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TWST trades at $132.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TWST's P/E ratio is -59.80. In terms of profitability, AMLX's ROE is -0.53%, compared to TWST's ROE of -0.30%. Regarding short-term risk, AMLX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check TWST's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
AMLX vs IMGN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas IMGN's P/E ratio is -111.55. In terms of profitability, AMLX's ROE is -0.53%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, AMLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
AMLX vs CAI Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CAI has a market cap of 8.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CAI trades at $30.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CAI's P/E ratio is 85.87. In terms of profitability, AMLX's ROE is -0.53%, compared to CAI's ROE of +0.19%. Regarding short-term risk, AMLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check CAI's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
AMLX vs KYMR Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while KYMR trades at $104.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas KYMR's P/E ratio is -32.73. In terms of profitability, AMLX's ROE is -0.53%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, AMLX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
AMLX vs CYTK Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CYTK trades at $61.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CYTK's P/E ratio is -8.58. In terms of profitability, AMLX's ROE is -0.53%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, AMLX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CYTK's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
AMLX vs APGE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas APGE's P/E ratio is -31.19. In terms of profitability, AMLX's ROE is -0.53%, compared to APGE's ROE of -0.30%. Regarding short-term risk, AMLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
AMLX vs BPMC Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BPMC's P/E ratio is -51.58. In terms of profitability, AMLX's ROE is -0.53%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, AMLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check BPMC's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
AMLX vs PTGX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, PTGX has a market cap of 8.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while PTGX trades at $128.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas PTGX's P/E ratio is 125.00. In terms of profitability, AMLX's ROE is -0.53%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, AMLX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
AMLX vs TGTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TGTX trades at $53.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TGTX's P/E ratio is 19.55. In terms of profitability, AMLX's ROE is -0.53%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, AMLX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check TGTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
AMLX vs AXSM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while AXSM trades at $157.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas AXSM's P/E ratio is -41.01. In terms of profitability, AMLX's ROE is -0.53%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, AMLX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check AXSM's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
AMLX vs CERE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CERE's P/E ratio is -16.47. In terms of profitability, AMLX's ROE is -0.53%, compared to CERE's ROE of -0.72%. Regarding short-term risk, AMLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CERE's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
AMLX vs ARWR Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ARWR has a market cap of 7.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ARWR trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ARWR's P/E ratio is -24.85. In terms of profitability, AMLX's ROE is -0.53%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, AMLX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ARWR's competition here
Metsera, Inc. (NASDAQ: MTSR)
AMLX vs MTSR Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MTSR's P/E ratio is -23.58. In terms of profitability, AMLX's ROE is -0.53%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, AMLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check MTSR's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
AMLX vs SYRE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while SYRE trades at $79.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas SYRE's P/E ratio is -40.97. In terms of profitability, AMLX's ROE is -0.53%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, AMLX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check SYRE's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
AMLX vs IONS Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, IONS has a market cap of 7.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while IONS trades at $42.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas IONS's P/E ratio is -13.13. In terms of profitability, AMLX's ROE is -0.53%, compared to IONS's ROE of -1.11%. Regarding short-term risk, AMLX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
AMLX vs MRUS Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MRUS's P/E ratio is -17.05. In terms of profitability, AMLX's ROE is -0.53%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, AMLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check MRUS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
AMLX vs PRAX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while PRAX trades at $241.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas PRAX's P/E ratio is -18.70. In terms of profitability, AMLX's ROE is -0.53%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, AMLX is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check PRAX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
AMLX vs ACLX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ACLX's P/E ratio is -28.27. In terms of profitability, AMLX's ROE is -0.53%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, AMLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
AMLX vs RETA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RETA's P/E ratio is -66.29. In terms of profitability, AMLX's ROE is -0.53%, compared to RETA's ROE of +0.47%. Regarding short-term risk, AMLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check RETA's competition here
Abivax S.A. (NASDAQ: ABVX)
AMLX vs ABVX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ABVX trades at $88.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ABVX's P/E ratio is -14.44. In terms of profitability, AMLX's ROE is -0.53%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, AMLX is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
AMLX vs CNTA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CNTA's P/E ratio is -22.63. In terms of profitability, AMLX's ROE is -0.53%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, AMLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CNTA's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
AMLX vs IOVA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, IOVA has a market cap of 6.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while IOVA trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas IOVA's P/E ratio is -18.66. In terms of profitability, AMLX's ROE is -0.53%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, AMLX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check IOVA's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
AMLX vs TERN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TERN's P/E ratio is -51.41. In terms of profitability, AMLX's ROE is -0.53%, compared to TERN's ROE of -0.14%. Regarding short-term risk, AMLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check TERN's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
AMLX vs RYTM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RYTM trades at $86.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RYTM's P/E ratio is -27.71. In terms of profitability, AMLX's ROE is -0.53%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, AMLX is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check RYTM's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
AMLX vs LGND Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while LGND trades at $295.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas LGND's P/E ratio is 32.44. In terms of profitability, AMLX's ROE is -0.53%, compared to LGND's ROE of +0.20%. Regarding short-term risk, AMLX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
AMLX vs BLTE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while BLTE trades at $142.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas BLTE's P/E ratio is -76.47. In terms of profitability, AMLX's ROE is -0.53%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, AMLX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check BLTE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
AMLX vs CDTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CDTX's P/E ratio is -19.77. In terms of profitability, AMLX's ROE is -0.53%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, AMLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
AMLX vs ABCM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, AMLX's ROE is -0.53%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, AMLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ABCM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
AMLX vs IMVT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while IMVT trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas IMVT's P/E ratio is -9.48. In terms of profitability, AMLX's ROE is -0.53%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, AMLX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check IMVT's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
AMLX vs ISEE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ISEE's P/E ratio is -22.44. In terms of profitability, AMLX's ROE is -0.53%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, AMLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ISEE's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
AMLX vs KOD Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, KOD has a market cap of 5.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while KOD trades at $85.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas KOD's P/E ratio is -20.56. In terms of profitability, AMLX's ROE is -0.53%, compared to KOD's ROE of -2.73%. Regarding short-term risk, AMLX is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check KOD's competition here
CG Oncology Inc. (NASDAQ: CGON)
AMLX vs CGON Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CGON trades at $59.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CGON's P/E ratio is -22.25. In terms of profitability, AMLX's ROE is -0.53%, compared to CGON's ROE of -0.25%. Regarding short-term risk, AMLX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CGON's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
AMLX vs APLS Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas APLS's P/E ratio is 38.35. In terms of profitability, AMLX's ROE is -0.53%, compared to APLS's ROE of +0.40%. Regarding short-term risk, AMLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check APLS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
AMLX vs MIRM Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MIRM trades at $80.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MIRM's P/E ratio is -5.51. In terms of profitability, AMLX's ROE is -0.53%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, AMLX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
AMLX vs COGT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while COGT trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas COGT's P/E ratio is -13.99. In terms of profitability, AMLX's ROE is -0.53%, compared to COGT's ROE of -0.73%. Regarding short-term risk, AMLX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
AMLX vs PTCT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, PTCT has a market cap of 4.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while PTCT trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas PTCT's P/E ratio is -25.42. In terms of profitability, AMLX's ROE is -0.53%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, AMLX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
AMLX vs SRRK Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while SRRK trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas SRRK's P/E ratio is -11.57. In terms of profitability, AMLX's ROE is -0.53%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, AMLX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check SRRK's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
AMLX vs CRSP Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CRSP trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CRSP's P/E ratio is -10.35. In terms of profitability, AMLX's ROE is -0.53%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, AMLX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CRSP's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
AMLX vs ORKA Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ORKA has a market cap of 4.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ORKA trades at $71.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ORKA's P/E ratio is -37.08. In terms of profitability, AMLX's ROE is -0.53%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, AMLX is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ORKA's competition here
Erasca, Inc. (NASDAQ: ERAS)
AMLX vs ERAS Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ERAS trades at $13.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ERAS's P/E ratio is -14.40. In terms of profitability, AMLX's ROE is -0.53%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, AMLX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
AMLX vs TVTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TVTX's P/E ratio is -110.22. In terms of profitability, AMLX's ROE is -0.53%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, AMLX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
AMLX vs FOLD Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas FOLD's P/E ratio is -161.00. In terms of profitability, AMLX's ROE is -0.53%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, AMLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check FOLD's competition here
Veradermics, Incorporated (NYSE: MANE)
AMLX vs MANE Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MANE trades at $108.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MANE's P/E ratio is -34.64. In terms of profitability, AMLX's ROE is -0.53%, compared to MANE's ROE of -0.38%. Regarding short-term risk, AMLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check MANE's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
AMLX vs AKRO Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas AKRO's P/E ratio is -14.57. In terms of profitability, AMLX's ROE is -0.53%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, AMLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
AMLX vs ALPN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ALPN's P/E ratio is -101.52. In terms of profitability, AMLX's ROE is -0.53%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, AMLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
AMLX vs DFTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, DFTX has a market cap of 4.3B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while DFTX trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas DFTX's P/E ratio is N/A. In terms of profitability, AMLX's ROE is -0.53%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, AMLX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check DFTX's competition here
Opthea Limited (NASDAQ: OPT)
AMLX vs OPT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas OPT's P/E ratio is -1.52. In terms of profitability, AMLX's ROE is -0.53%, compared to OPT's ROE of +1.18%. Regarding short-term risk, AMLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
AMLX vs PRTC Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas PRTC's P/E ratio is -3.78. In terms of profitability, AMLX's ROE is -0.53%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, AMLX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
AMLX vs MRTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas MRTX's P/E ratio is -4.82. In terms of profitability, AMLX's ROE is -0.53%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, AMLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check MRTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
AMLX vs DNTH Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while DNTH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas DNTH's P/E ratio is -17.39. In terms of profitability, AMLX's ROE is -0.53%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, AMLX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check DNTH's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
AMLX vs EWTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while EWTX trades at $37.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas EWTX's P/E ratio is -20.10. In terms of profitability, AMLX's ROE is -0.53%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, AMLX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check EWTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
AMLX vs CPRX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CPRX's P/E ratio is 17.49. In terms of profitability, AMLX's ROE is -0.53%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, AMLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CPRX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
AMLX vs ADPT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ADPT has a market cap of 3.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ADPT trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ADPT's P/E ratio is -58.59. In terms of profitability, AMLX's ROE is -0.53%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, AMLX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check ADPT's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
AMLX vs ABCL Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ABCL trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ABCL's P/E ratio is -21.85. In terms of profitability, AMLX's ROE is -0.53%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, AMLX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
AMLX vs RYZB Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RYZB's P/E ratio is -57.86. In terms of profitability, AMLX's ROE is -0.53%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, AMLX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
AMLX vs CBAY Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas CBAY's P/E ratio is -32.81. In terms of profitability, AMLX's ROE is -0.53%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, AMLX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check CBAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
AMLX vs TNGX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TNGX trades at $22.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TNGX's P/E ratio is -26.55. In terms of profitability, AMLX's ROE is -0.53%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, AMLX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
AMLX vs TLX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while TLX trades at $10.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas TLX's P/E ratio is 111.59. In terms of profitability, AMLX's ROE is -0.53%, compared to TLX's ROE of +0.07%. Regarding short-term risk, AMLX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check TLX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
AMLX vs ARQT Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while ARQT trades at $28.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas ARQT's P/E ratio is 137.33. In terms of profitability, AMLX's ROE is -0.53%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, AMLX is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
AMLX vs RLAY Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, RLAY has a market cap of 3.6B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while RLAY trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas RLAY's P/E ratio is -10.37. In terms of profitability, AMLX's ROE is -0.53%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, AMLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check RLAY's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
AMLX vs SWTX Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas SWTX's P/E ratio is -13.78. In terms of profitability, AMLX's ROE is -0.53%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, AMLX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for AMLX.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
AMLX vs LEGN Comparison October 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMLX stands at 3.3B. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, AMLX is priced at $26.34 on the NASDAQ, while LEGN trades at $18.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMLX currently has a P/E ratio of -17.56, whereas LEGN's P/E ratio is -27.10. In terms of profitability, AMLX's ROE is -0.53%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, AMLX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for AMLX.Check LEGN's competition here